EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine HCl): Technical Guidance for Laboratory Workflows

What This Product Solves

EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride; CAS 25952-53-8) is a water-soluble carbodiimide reagent optimized for the activation of carboxyl groups during amide bond formation. It is primarily used as a peptide synthesis coupling reagent and for bioconjugation, where it facilitates the linkage of primary amines to carboxyl-containing biomolecules. This reagent is also applicable to nucleotide synthesis and select esterification and lactonization reactions in aqueous or mixed-solvent systems. By enabling efficient coupling in aqueous conditions without the need for organic co-reagents, EDC.HCl streamlines workflows that require rapid, controlled amide formation. It is not intended for use in living systems or clinical protocols due to the absence of safety or pharmacokinetic data (product information).

For further context on practical applications, the internal article EDC.HCl: Practical Guidance for Peptide Synthesis and Bioconjugation details in vitro workflow boundaries, and EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine HCl): Actionable Protocol Guide offers stepwise setup recommendations for peptide and nucleotide coupling.

Protocol Parameters

• Solubility (water) | ≥39 mg/mL | Dissolution of reagent for aqueous coupling reactions | Ensures sufficient reagent concentration in standard peptide synthesis and bioconjugation protocols | product dossier
• Recommended storage (solid) | -20°C, desiccated | Long-term preservation of EDC.HCl | Maintains chemical integrity and prevents hydrolysis prior to use | product dossier
• Solution stability | Use immediately after preparation; avoid long-term storage | All coupling and conjugation workflows | EDC.HCl solutions are prone to hydrolysis in aqueous media, which decreases coupling efficiency | product dossier
• Monitoring (quantitative) | Spectrophotometric methods | QC for reagent consumption and byproduct formation | Permits real-time tracking of reaction progress and EDC depletion | product dossier
• Solubility (DMSO, ethanol) | ≥19.2 mg/mL (DMSO), ≥39.6 mg/mL (ethanol) | Alternative dissolution for specific substrates | Allows protocol adaptation for poorly water-soluble reactants | product dossier
• Reaction pH | pH 4.5–7.5 (workflow recommendation) | Amide bond formation efficiency | Optimal coupling rates and minimal hydrolysis occur in this range | workflow recommendation

Workflow Setup and QC Checklist

1. Reagent Preparation: Weigh EDC.HCl under anhydrous conditions. Dissolve in water, DMSO, or ethanol as dictated by substrate solubility; use freshly prepared solutions to avoid hydrolysis.
2. pH Control: Adjust the reaction buffer to pH 4.5–7.5 for optimal coupling rates. Monitor pH throughout, as carbodiimide-mediated activation is sensitive to pH drift.
3. Substrate Addition: Add carboxyl- and amine-containing reactants sequentially or simultaneously, ensuring both are fully dissolved.
4. Catalyst or Additive Use: For challenging substrates, consider adding N-hydroxysuccinimide (NHS) or sulfo-NHS to stabilize activated intermediates and suppress side-product formation.
5. Reaction Monitoring: Use spectrophotometric tracking of EDC or urea byproduct to verify reaction completion, as specified in the product dossier.
6. Workup: Remove byproducts and unreacted EDC by appropriate purification (e.g., dialysis, chromatography), as residual urea can interfere with downstream assays.
7. QC Confirmation: Analyze coupled products by HPLC, MS, or gel electrophoresis to confirm successful amide bond or ester formation.

Common Failure Modes and Fixes

• Reagent Decomposition: EDC.HCl rapidly hydrolyzes in aqueous solution, leading to decreased coupling efficiency. Fix: Prepare solutions immediately before use, and minimize exposure to moisture during weighing and transfer.
• Low Coupling Yield: Suboptimal pH or incorrect stoichiometry can reduce product formation. Fix: Adjust pH within the 4.5–7.5 range; verify reactant concentrations and use a slight excess of EDC.HCl if necessary.
• Side-Product Formation: O-acylisourea or N-acylurea byproducts may form, particularly in the absence of stabilizing additives. Fix: Incorporate NHS or sulfo-NHS to trap activated intermediates and improve selectivity for amide bond formation.
• Precipitation or Solubility Issues: Some substrates or products may precipitate during reaction. Fix: Switch solvent systems (DMSO or ethanol), or increase reaction volume and agitation.
• Inconsistent Results Between Batches: Variability in reagent quality or storage conditions can impact outcomes. Fix: Store EDC.HCl desiccated at -20°C and avoid freeze-thaw cycles.

Scope and Limitations

EDC.HCl is validated as a peptide synthesis coupling reagent, bioconjugation reagent, and nucleotide synthesis reagent in strictly in vitro protocols. Its water solubility allows straightforward integration into aqueous workflows, but sensitivity to hydrolysis limits its working solution lifetime. The reagent is not recommended for in vivo or clinical studies, as there are no published data supporting such use. Additionally, while effective for amide and certain ester linkages, it may not be suitable for substrates requiring highly anhydrous or nonaqueous conditions, unless fully dissolved in DMSO or ethanol as supported by solubility data from the APExBIO product page. Always consult the most recent product documentation before protocol modification.

Conclusion

EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a robust choice for in vitro peptide synthesis, bioconjugation, and nucleotide coupling workflows requiring rapid and efficient amide bond formation. Adherence to recommended storage, handling, and reaction parameters is critical to reproducibility and yield. For further workflow optimization, refer to related technical articles and confirm procedural details with product documentation. Use of this reagent should remain confined to laboratory research settings, as clinical or in vivo applicability has not been established.